insulin degludec innusan ultralongacting basal insulin analogue developed novo nordisk brand name administered via subcutaneous injection daily help control blood sugar level diabetes duration action lasts hours compared hours provided marketed longacting insulins insulin glargine insulin detemir making oncedaily basal one provides base insulin level opposed fast shortacting bolus insulins insulin degludec modified insulin one single amino acid deleted comparison human insulin conjugated hexadecanedioic acid via gammalglutamyl spacer amino acid lysine position included world health organizations list essential equivalent insulin glargine commonly prescribed medication united states million significant side effect insulin therapy hypoglycemia metaanalysis clinical trials published july found events hypoglycemia defined blood glucose mgdl per patient year higher rates concentrated degludec formulation rates nocturnal hypoglycemia ranged events per patient recent cochrane systematic review found significant differences rates diurnal nocturnal hypoglycemia studies outcomes using insulin degludec compared insulin glargine insulin detemir nph insulin management type diabetes neither adults insulin degludec ultralong acting insulin unlike insulin glargine active physiologic ph addition hexadecanedioic acid via amide linkage lysine position allows formation multihexamers subcutaneous allows formation subcutaneous depot results slow insulin release systemic insulin degludec onset action minutes similar insulin glargine insulin detemir peak activity due slow release systemic circulation duration action insulin degludec reported longer halflife longer hours approved daily dosing time day long hours elapsed since previous missed dose advised taken soon remembered return normal studies shown patients taking insulin degludec needed take significantly smaller doses basal insulin taking insulin glargine achieving similar blood glucose levels however recent cochrane systematic review clinically significant differences measures effectiveness found using insulin degludec compared insulin glargine insulin detemir nph insulin management type diabetes neither adults insulin degludec also ability mixed insulins thereby improving glycemic control done using current longacting physician involved trials quoted saying allows creation novel formulation retains smooth control longacting basal rapidacting mealtime control insulin aspart insulin retains ultralow risk characteristics degludec simultaneous mealtime insulin degludec filed registration united completion additional cardiac safety studies requested us food drug administration fda february received fda approval september marketing began january insulin degludec studied alternative insulin glargine part basalbolus regimen begin basalbolus type trial patients type diabetes randomized ratio either insulin degludec insulin glargine addition mealtime insulin aspart patients degludec treatment arm switched basal insulin insulin degludec ratio dose reduction patients receiving multiple basal doses per day weeks patients treated insulin degludec produced similar reduction vs meeting criteria noninferiority adverse events similar two treatment arms however rates nocturnal hypoglycemia midnight lower patients treated insulin degludec vs reduction incidence hypoglycemia seen therapeutic benefit hypoglycemia often dose limiting toxicity insulin cochrane systematic review compared use insulin degludec insulin glargine insulin detemir nph insulin adults children diagnosed type review included randomized control trials rcts duration weeks total sample participants randomized across studies participants allocated nph insulin participants insulin detemir participants insulin glargine participants insulin degludec participants children studies directly compared insulin degludec nph insulin studies comparing insulin degludec insulin detemir rcts insulin degludec insulin glargine rcts clinically relevant difference found outcomes allcause mortality healthrelated quality life qol severe hypoglycemia nonfatal myocardial infarctionstroke nfminfs severe nocturnal hypoglycaemia serious adverse effects sae glycosated haemoglobin begin basalbolus type trial insulin degludec studied alternative insulin glargine patients type diabetes mellitus patients randomized receive either insulin degludec insulin glargine addition either mealtime insulin aspart metformin andor pioglitazone patients trial average regimen consisting basalbolus insulin plus oral antidiabetic medications weeks insulin degludec found noninferior insulin glargine providing similar lowering effect vs overall rates hypoglycemia significantly lower insulin degludec vs including cases nocturnal hypoglycemia vs given treattotarget nature begin trial program much health economic analysis insulin degludec focussed shortterm costeffectiveness based differences insulin dosing hypoglycemic event incidence rather differences glycemic first costeffectiveness analysis nature conducted societal perspective swedish setting finding insulin degludec would costeffective relative insulin glargine treatment type diabetes type diabetes part either basal basalinsulin httpsenwikipediaorgwikiinsulindegludec